Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Elixinol Wellness Limited is an Australian-based hemp-derived CBD and wellness products company operating in the nutraceutical and specialty pharmaceutical space. The company manufactures and distributes hemp-based consumer products including CBD oils, topicals, and dietary supplements primarily across Australia, the US, and Europe. With a market cap effectively near zero and severe cash burn, the company faces existential liquidity challenges despite 80.9% revenue growth, trading at distressed valuations (0.1x P/S, 0.3x P/B) following a 72% decline over the past year.
Elixinol sources hemp biomass, extracts CBD and other cannabinoids through proprietary or third-party processing, then formulates finished consumer products sold through e-commerce channels, retail partnerships, and pharmacy networks. The 35.8% gross margin reflects commodity input costs (hemp biomass pricing), extraction efficiency, and competitive pricing pressure in an increasingly crowded CBD market. The company lacks meaningful pricing power due to regulatory uncertainty, limited brand differentiation, and competition from both established pharmaceutical companies and smaller CBD startups. Negative operating margins (-23.2%) indicate the company is burning cash on marketing, compliance, and overhead faster than it can scale revenue.
Regulatory developments in CBD/cannabis legislation across Australia, US (FDA guidance), and EU markets - approval pathways or restrictions dramatically impact addressable market
Cash runway announcements and capital raises - with negative FCF and 0.92x current ratio, equity dilution or debt financing events are critical near-term catalysts
Revenue growth sustainability and gross margin trends - market questioning whether 80.9% growth is sustainable or reflects easy comps from depressed base
Strategic partnerships or M&A activity - potential acquisition by larger pharmaceutical/consumer health company or distribution agreements with major retailers
Clinical trial results or health claims approvals - ability to make therapeutic claims versus wellness positioning affects pricing power and market access
Regulatory uncertainty remains the dominant structural risk - FDA has not established clear pathways for CBD in food/supplements in the US, Australia's TGA maintains restrictive scheduling, and EU novel food regulations create market access barriers. Adverse regulatory decisions could eliminate entire revenue channels.
Commoditization of CBD products as barriers to entry are low - hundreds of competitors with minimal differentiation, leading to price compression and margin erosion. Large pharmaceutical and consumer packaged goods companies entering the space with superior distribution and brand equity.
Scientific evidence gaps for efficacy claims limit premium pricing - without robust clinical data supporting health benefits beyond anecdotal evidence, products remain positioned as low-margin wellness commodities rather than therapeutic solutions
Competition from vertically integrated cannabis companies (Canopy Growth, Tilray) with deeper capital bases, established distribution networks, and diversified product portfolios including THC products in legal markets
Retail pharmacy chains and e-commerce giants (Amazon potentially entering CBD space) could leverage existing customer relationships and logistics infrastructure to capture market share with private label products at lower price points
Brand erosion risk as quality control issues in the broader CBD industry (mislabeling, contamination) create consumer skepticism affecting all players
Liquidity crisis risk - current ratio of 0.92x and negative operating cash flow indicate the company may not meet short-term obligations without additional financing. With market cap near zero, equity raises would be massively dilutive to existing shareholders.
Going concern risk - auditors may issue going concern warnings if cash runway falls below 12 months without credible financing plan, triggering covenant violations or supplier payment terms tightening
Asset impairment risk - inventory obsolescence (CBD products have shelf life), goodwill/intangible writedowns from prior acquisitions, or property/equipment impairments if operations are consolidated
moderate-to-high - CBD wellness products are discretionary purchases that compress during economic downturns as consumers prioritize essential spending. However, the wellness/supplement category has shown resilience relative to other discretionary categories. Industrial hemp cultivation economics are sensitive to agricultural commodity cycles and farmer planting decisions, affecting input costs. Consumer sentiment and disposable income directly impact DTC conversion rates and average order values.
High sensitivity through multiple channels: (1) Rising rates increase cost of capital for a cash-burning business requiring external financing, making equity raises more dilutive and debt more expensive; (2) Higher rates compress valuation multiples for unprofitable growth companies, particularly in speculative sectors like CBD; (3) Consumer financing costs (credit cards, personal loans) may reduce discretionary wellness spending. The company's distressed valuation suggests rate-driven multiple compression has already occurred.
Moderate - The company's 0.45x debt/equity ratio indicates some leverage, and with negative cash flow, refinancing risk exists if credit conditions tighten. Access to growth capital (equity or convertible debt) is critical for survival, making credit market conditions and risk appetite for speculative healthcare/consumer plays a key variable. Tighter credit reduces acquisition financing for potential strategic buyers.
Highly speculative momentum/turnaround investors willing to accept binary outcomes - either the company secures financing and regulatory tailwinds materialize (potential multi-bagger from distressed levels) or it faces insolvency/massive dilution. The 72% one-year decline and negative cash flow profile have eliminated institutional holders and dividend/value investors. Only risk-tolerant retail or distressed debt specialists would consider current positioning. Volatility profile is extreme given liquidity constraints and binary catalysts.
high - Stock exhibits extreme volatility driven by low liquidity (near-zero market cap), binary regulatory/financing catalysts, and speculative positioning. Historical price action shows susceptibility to 20-40% single-day moves on material news. Beta likely exceeds 2.0x relative to broader healthcare indices, with idiosyncratic risk dominating systematic risk.
